A study involving 292 women from five countries found that daily injection of the blood thinner antepartum dalteparin into the stomachs of pregnant women with thrombophilia was not effective in reducing pregnancy complications such as placenta blood clots. The findings, published in The Lancet, will allow researchers "to move on, to pursue other, potentially effective, methods for treating pregnant women with thrombophilia and/or complications from placenta blood clots," the study authors said.

Full Story:

Related Summaries